143 related articles for article (PubMed ID: 2295068)
21. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
24. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
25. Effect of five antineoplastic agents on tumor xenografts with different growth rates.
Mattern J; Wayss K; Volm M
J Natl Cancer Inst; 1984 Jun; 72(6):1335-9. PubMed ID: 6587154
[TBL] [Abstract][Full Text] [Related]
26. [Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma].
Uchida T; Okamoto K; Nishikawa K; Takahashi K
Gan To Kagaku Ryoho; 1986 Jan; 13(1):75-9. PubMed ID: 3753643
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts.
Langmuir VK; Rooker JA; Osen M; Mendonca HL; Laderoute KR
Cancer Res; 1994 Jun; 54(11):2845-7. PubMed ID: 8187065
[TBL] [Abstract][Full Text] [Related]
28. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Nath K; Nelson DS; Putt ME; Leeper DB; Garman B; Nathanson KL; Glickson JD
PLoS One; 2016; 11(6):e0157125. PubMed ID: 27285585
[TBL] [Abstract][Full Text] [Related]
30. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
31. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
32. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
33. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.
Schold SC; Friedman HS; Bjornsson TD; Bigner DD
Cancer Res; 1984 Jun; 44(6):2352-7. PubMed ID: 6722774
[TBL] [Abstract][Full Text] [Related]
34. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
35. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
36. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
37. Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: analysis of the VETOPEC regimen.
White L; Sterling-Levis K
J Clin Neurosci; 2008 Jan; 15(1):49-54. PubMed ID: 18036819
[TBL] [Abstract][Full Text] [Related]
38. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
Castellino SM; Friedman HS; Elion GB; Ong ET; Marcelli SL; Page R; Bigner DD; Dewhirst MW
Br J Cancer; 1995 Jun; 71(6):1181-7. PubMed ID: 7779708
[TBL] [Abstract][Full Text] [Related]
39. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
40. Ultrasonic hyperthermia and drugs as therapy for human tumor xenografts.
Senapati N; Houchens D; Ovejera A; Beard R; Nines R
Cancer Treat Rep; 1982 Aug; 66(8):1635-9. PubMed ID: 7105053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
